Akums Drugs & Pharmaceuticals Ltd

Akums Drugs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Akums Drugs & Pharmaceuticals Ltd

₹ 471 0.74%
04 Nov - close price
akums.in BSE: 544222 NSE: AKUMS
About

Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services.[1]

Key Points

Business Profile[1] Akums Drugs is a Contract Development and Manufacturing Organization (CDMO) manufacturing tablets, capsules, liquid orals, vials, ampoules, blow-filled seals, topical preparations, eye drops, dry powder injections, and gummies.

Website BSE NSE
  • Market Cap ₹ 7,415 Cr.
  • Current Price ₹ 471
  • High / Low ₹ 844 / 405
  • Stock P/E 22.5
  • Book Value ₹ 194
  • Dividend Yield 0.00 %
  • ROCE 16.2 %
  • ROE 17.2 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 48.9% CAGR over last 5 years

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 11.3% over past five years.
  • Company has a low return on equity of 13.1% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap Nifty MidSmallcap 400

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
970 1,181 1,083 944 1,019 1,033 1,010 1,056 1,024
1,095 1,029 989 941 891 912 889 962 895
Operating Profit -125 152 93 3 128 121 121 94 129
OPM % -13% 13% 9% 0% 13% 12% 12% 9% 13%
8 -21 10 10 7 17 19 26 27
Interest 12 14 12 12 13 12 5 5 23
Depreciation 30 30 32 34 34 35 45 40 37
Profit before tax -159 87 59 -33 87 92 91 75 96
Tax % 18% 62% -229% 20% 30% 27% 27% -99% 32%
-187 33 195 -39 61 67 66 150 65
EPS in Rs -13.16 2.22 13.54 -2.89 4.08 4.14 4.14 9.38 4.03
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
1,464 1,651 2,414 2,723 3,672 3,655 4,178 4,118 4,123
1,340 1,507 2,240 2,485 3,761 3,361 4,055 3,654 3,658
Operating Profit 124 144 174 237 -89 294 123 465 465
OPM % 8% 9% 7% 9% -2% 8% 3% 11% 11%
6 6 26 12 7 15 8 69 89
Interest 23 22 20 7 17 46 51 35 45
Depreciation 31 38 67 70 95 113 126 153 156
Profit before tax 77 89 114 172 -193 150 -45 345 353
Tax % 51% 50% 62% 28% 30% 35% -102% 0%
43 61 44 123 -251 98 1 344 347
EPS in Rs 366.55 523.23 335.61 949.10 -35.30 6.63 -0.28 21.49 21.69
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 11%
5 Years: 11%
3 Years: 4%
TTM: -2%
Compounded Profit Growth
10 Years: 22%
5 Years: 49%
3 Years: 49%
TTM: 30%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: -43%
Return on Equity
10 Years: %
5 Years: 7%
3 Years: 13%
Last Year: 17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 1 1 1 1 14 29 29 31
Reserves 493 628 721 884 608 689 681 3,016
255 213 175 97 395 619 565 88
293 318 1,140 1,170 2,033 1,905 2,229 960
Total Liabilities 1,042 1,161 2,037 2,152 3,050 3,241 3,504 4,095
444 501 645 834 1,021 1,097 1,191 1,397
CWIP 0 11 57 87 31 103 195 163
Investments 0 18 6 19 0 0 0 0
598 632 1,329 1,212 1,998 2,041 2,118 2,535
Total Assets 1,042 1,161 2,037 2,152 3,050 3,241 3,504 4,095

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
72 89 28 135 32 177 498 465
-150 -123 -190 -109 -235 -305 -331 -548
66 37 233 -95 236 125 -108 73
Net Cash Flow -11 4 71 -70 33 -4 59 -10

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 68 57 88 71 88 84 73 68
Inventory Days 114 115 99 93 112 117 90 102
Days Payable 67 60 105 74 92 91 76 96
Cash Conversion Cycle 115 112 82 90 109 111 87 74
Working Capital Days 78 73 55 66 49 46 40 71
ROCE % 14% 20% -16% 22% 2% 16%

Shareholding Pattern

Numbers in percentages

Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
75.26% 75.26% 75.26% 75.26% 75.26%
7.34% 6.36% 5.77% 4.24% 2.27%
7.53% 6.99% 7.39% 8.85% 9.28%
7.14% 8.64% 8.84% 8.92% 10.46%
2.73% 2.73% 2.73% 2.73% 2.73%
No. of Shareholders 57,53168,41069,36669,42475,365

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls